A new study presented at the European Psychiatric Association Congress 2024 reveals a significant association between prenatal cannabis use disorder (CUD) and adverse mental health outcomes in offspring. The study highlights the importance of addressing CUD during pregnancy to mitigate potential risks to the developing child.
Washington — Cases of a rare cannabis-related condition increased significantly in one Michigan hospital after the state legalized marijuana, raising concerns about the potential health implications of widespread cannabis use. The findings underscore the need for further research into the long-term effects of cannabis consumption.
There is ongoing uncertainty about whether cannabis use increases the risk of developing an anxiety disorder. In this study, we estimated the risk of developing anxiety disorders among cannabis users and found a potential link between cannabis use and increased anxiety symptoms.
Clozapine, oral aripiprazole, and long-acting injectable (LAI) formulations of risperidone, aripiprazole, and paliperidone have been shown to decrease the risk of adverse outcomes in individuals with cannabis use disorder. These medications may offer a promising treatment option for those struggling with CUD.
Regular cannabis users, who smoked more than once per month, had a significantly poorer COVID-19-related survival rate, even after adjusting for known risk factors. This highlights the importance of understanding the potential impact of cannabis use on overall health outcomes.
Despite the benefits associated with longer buprenorphine treatment duration for opioid use disorder, there is limited research on the effectiveness of this approach for individuals with co-occurring cannabis use disorder. Further studies are needed to explore the potential benefits of extended buprenorphine treatment for this population.
ICD-10-CM seems to have returned to more normal volumes of new codes with 191 new codes, 159 of which are billable codes set to launch this October. This update may provide clinicians with more accurate tools for diagnosing and treating cannabis use disorder and related mental health conditions.
Rates of repeat hospitalizations for reasons related to mental health and substance use have been increasing in Canada, from 11.6% in 2013 to 13.5% in 2021. This trend highlights the need for comprehensive and integrated care approaches to address the complex needs of individuals with co-occurring mental health and substance use disorders.
Background: Tobacco smoking confounds CVD risk studies. No large-scale investigation has been performed yet to examine cannabis use disorder and its impact on cardiovascular health. Further research is needed to understand the potential cardiovascular risks associated with cannabis use disorder and inform preventive strategies.
